• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings

    6/18/25 2:04:00 PM ET
    $EYEN
    $KIDZ
    $LGHL
    $VVPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $EYEN alert in real time by email

    NEW YORK, June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series of transactions that bridge traditional capital markets with the rapidly evolving world of blockchain and cryptocurrency.

    Chardan logo (PRNewsfoto/Chardan)

    As part of its strategic push into crypto finance, Chardan has recently served as a strategic advisor and placement agent in the following notable transactions:

    Eyenovia's $50 Million PIPE to Acquire HYPE Tokens

    Chardan acted as sole placement agent in Eyenovia Inc.'s (NASDAQ:EYEN) $50 million PIPE financing. The proceeds are being used to acquire over 1 million HYPE tokens, the native asset of the Hyperliquid blockchain, making Eyenovia the first U.S.-listed company to hold HYPE in its treasury.

    This transaction positions Eyenovia as a top validator on the Hyperliquid network and includes a strategic staking initiative in partnership with Anchorage Digital. The financing involved the issuance of non-voting convertible preferred stock and warrants, potentially raising up to $150 million in total proceeds.

    Lion Group's $600 Million Facility to Launch Hyperliquid Strategy

    Chardan acted as sole placement agent in Lion Group Holding's (NASDAQ:LGHL) $600 million facility. The facility supports the strategic accumulation of HYPE as a reserve asset, alongside Solana (SOL) and Sui (SUI). This represents LGHL's relaunch of crypto operations and its pivot toward decentralized finance infrastructure.

    VivoPower's $121 Million PIPE to Launch XRP Treasury Strategy

    Chardan acted as placement agent for the $121 million private placement for VivoPower International PLC (NASDAQ:VVPR). VivoPower is believed to be the first public company to implement an XRP-focused digital asset treasury strategy. Proceeds will be used to acquire XRP, build out a decentralized finance team, and contribute to the XRPL ecosystem.

    Classover's $500 Million Convertible Notes for Solana Treasury Strategy

    Chardan served as financial advisor to Classover Holdings, Inc. (NASDAQ:KIDZ) in its $11 million initial tranche which is the first issuance under the $500 million senior secured convertible note financing.

    Under the terms of the financing agreement, approximately 80% of the net proceeds from the initial tranche will be allocated toward the purchase of Solana (SOL) tokens, subject to certain terms and limitations.

    Classover has already acquired over 6,400 SOL tokens and is exploring additional opportunities in staking and locked token acquisitions, reinforcing its commitment to blockchain-integrated financial strategy.

    Chardan's Vision for the Future of Finance

    "These transactions underscore our commitment to leading the convergence of traditional finance and digital assets," said Jonas Grossman, President and Managing Partner at Chardan. "We are proud to support visionary companies like Eyenovia, VivoPower, Classover, and Lion Group Holding as they redefine capital allocation and treasury management in the Web3 era."

    Chardan continues to expand its digital asset advisory capabilities, offering bespoke capital markets solutions, tokenomics structuring, and blockchain integration strategies for forward-thinking clients.

    About Chardan:

    Chardan is an independent global investment bank specializing in healthcare, digital assets, technology, SPACs, and emerging growth companies. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access, and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, and NASDAQ. 

    Chardan Media Contact:

    Emily Levine

    Chief Commercial Officer

    [email protected] 

    (475) 400-6071

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/chardan-expands-into-digital-assets-by-advising-strategic-crypto-backed-financings-302485587.html

    SOURCE Chardan

    Get the next $EYEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYEN
    $KIDZ
    $LGHL
    $VVPR

    CompanyDatePrice TargetRatingAnalyst
    Eyenovia Inc.
    $EYEN
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $EYEN
    $KIDZ
    $LGHL
    $VVPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Eyenovia downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Eyenovia from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

      11/18/24 7:44:30 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eyenovia with a new price target

      HC Wainwright & Co. reiterated coverage of Eyenovia with a rating of Buy and set a new price target of $8.00 from $6.00 previously

      4/1/21 6:45:58 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Northland Capital initiated coverage on Eyenovia with a new price target

      Northland Capital initiated coverage of Eyenovia with a rating of Outperform and set a new price target of $10.00

      3/1/21 9:11:48 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    $KIDZ
    $LGHL
    $VVPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MYDCOMBI issued to EYENOVIA INC.

      Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/8/23 1:05:04 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    $KIDZ
    $LGHL
    $VVPR
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Classover Holdings Inc.

      PRE 14A - Classover Holdings, Inc. (0002022308) (Filer)

      6/18/25 4:30:11 PM ET
      $KIDZ
      Other Consumer Services
      Real Estate
    • SEC Form 6-K filed by Lion Group Holding Ltd.

      6-K - Lion Group Holding Ltd (0001806524) (Filer)

      6/18/25 8:46:06 AM ET
      $LGHL
      Investment Bankers/Brokers/Service
      Finance
    • Amendment: SEC Form S-1/A filed by Classover Holdings Inc.

      S-1/A - Classover Holdings, Inc. (0002022308) (Filer)

      6/18/25 8:40:19 AM ET
      $KIDZ
      Other Consumer Services
      Real Estate

    $EYEN
    $KIDZ
    $LGHL
    $VVPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Rowe Michael M bought $14,077 worth of shares (27,071 units at $0.52), increasing direct ownership by 33% to 109,998 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      8/28/24 8:01:36 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rowe Michael M bought $28,500 worth of shares (50,000 units at $0.57), increasing direct ownership by 152% to 82,927 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      8/27/24 1:06:37 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Grant Stuart M. bought $1,000,000 worth of shares (1,515,151 units at $0.66), increasing direct ownership by 16% to 10,914,153 units (SEC Form 4)

      4 - EYENOVIA, INC. (0001682639) (Issuer)

      7/3/24 3:18:06 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    $KIDZ
    $LGHL
    $VVPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group

      LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capital strategy. Avenue Capital Group, now the Company's largest common stockholder, has agreed to amend Eyenovia's senior secured debt to further support the Company as it builds its HYPE treasury and reserve of the HYPE token. Pursuant to the terms of the amendment, the maturity date of the debt has been extended from November 1, 2025 to

      6/18/25 8:32:42 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VivoPower to host Annual General Meeting on December 30, 2024 in London

      London, Dec. 06, 2024 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:VVPR) (the "Company" or "VivoPower") is pleased to announce that it will hold its Annual General Meeting ("AGM") at its offices in London on Monday, December 30, 2024, at 1:00 p.m. London time. The resolutions to be passed include: Laying of annual accounts and reportsDirectors' remuneration reportRe-appointment of auditorsRemuneration of auditorsExtension of the term of William Langdon appointment as director of the CompanyApproval for Mergers or Divestments The formal notice of the AGM with accompanying proxy forms and dial in details will be mailed to shareholders in accordance with the statutory period pri

      12/6/24 3:42:00 PM ET
      $VVPR
      Power Generation
      Utilities
    • Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

      NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of diverse finance and accounting leadership experience spanning therapeutics and medical technology/devices, most recently serving as Chief Financial Officer of NovaBay Pharmaceuticals, Inc., a publicly traded, commercial stage ophthalmic company. Eyenovia's current CFO, John Gandolfo, is retiring and will remain with

      9/3/24 7:00:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care